Tolerance of transcranial direct current stimulation in psychiatric disorders: An analysis of 2000+ sessions

Chhabra, Harleen; Bose, Anushree; Shivakumar, Venkataram; Agarwal, Sri Mahavir; Sreeraj, Vanteemar S.; Shenoy, Sonia; Hazari, Nandita; Dinakaran, Damodharan; Parlikar, Rujuta; Koparde, Vinayak; Ramesh, Vinutha; Biswal, Jitendriya; Murugaraja, Venkatachalam; Gowda, Shayanth Manche; Chand, Prabhat; Sivakumar, Palanimuthu T.; Kalmady, Sunil V.; Narayanaswamy, Janardhanan C.; Murthy, Pratima; Girimaji, Satish Chandra; Venkatasubramanian, Ganesan

doi:10.1016/j.psychres.2020.112744

Cited by 28 publications

(15 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, prolonged stimulation may modify synaptic plasticity via long-term potentiation or depression ( 17 , 25 ). tDCS is relatively low risk, with some patients reporting sleepiness, minor discomfort, or mild burning or pain in the neck or scalp ( 26 ).…”

Section: Introductionmentioning

confidence: 99%

Neuromodulation to Treat Substance Use Disorders in People With Schizophrenia and Other Psychoses: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

BackgroundSubstance use disorders (SUDs) are a common yet poorly studied comorbidity in individuals with psychotic disorders. The co-occurrence of the two complicates recovery and interferes with pharmacological and behavioral treatment response and adherence. Recently, researchers have been exploring both invasive and non-invasive neuromodulation techniques as potential treatment methods for SUDs. We review the evidence that neuromodulation may reduce substance craving and consumption in individuals with schizophrenia.MethodsA comprehensive literature search of PubMed, MEDLINE, and PsycINFO databases was conducted (N = 1,432). Of these, we identified seven studies examining the effects of repetitive transcranial magnetic stimulation (rTMS) and two studies using transcranial direct current stimulation (tDCS) on drug consumption and craving in schizophrenia or schizoaffective disorders.ResultsDespite the limited number of studies in this area, the evidence suggests that rTMS to the dorsolateral prefrontal cortex (DLPFC) may reduce cannabis and tobacco use in patients with schizophrenia and schizoaffective disorder. Findings with tDCS, however, were inconclusive.DiscussionOur systematic review suggests that rTMS applied to DLPFC is a safe and promising therapeutic technique for the management of comorbid schizophrenia and SUDs, with the majority of the evidence in tobacco use disorder. However, there was substantial heterogeneity in study methods, underscoring the need to optimize stimulation parameters (e.g., frequency, duration, and target regions). Larger clinical trials are needed to establish the efficacy of rTMS in reducing drug consumption and craving in psychotic patients, ideally in comparison to existing pharmacological and behavioral interventions.

show abstract

Section: Introductionmentioning

confidence: 99%

Neuromodulation to Treat Substance Use Disorders in People With Schizophrenia and Other Psychoses: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Tolerability: tDCS is better tolerated than ECT and rTMS. The established safety profile for tDCS [31][32][33] makes it a promising treatment option in the psychogeriatric population. There is almost no propensity of seizures with tDCS, and its safety has been proven in adult patients.…”

Section: Advantages Of Domiciliary Tdcsmentioning

confidence: 99%

“…Managing adverse effects: tDCS is a relatively safe method of neuromodulation. 32 However, there are several adverse effects of tDCS, most notable being local skin irritation, unpleasant sensations, headache, and cutaneous lesions. Although these may fall under the rubric of benign or mild adverse effects, they can lead to decreased adherence and increased caregiver/patient anxiety unless managed effectively.…”

Section: Limitations Of Domiciliary Tdcs and Possible Solutionsmentioning

confidence: 99%

See 1 more Smart Citation

Domiciliary tDCS in Geriatric Psychiatric Disorders: Opportunities and Challenges

Rangarajan

Suhas

Mukku

et al. 2021

Indian Journal of Psychological Medicine

Self Cite

View full text Add to dashboard Cite

Real-world implementation of nonpharmacological interventions for the behavioral and psychological symptoms of dementia is limited by the therapist's availability, willingness of the patient and family to participate, cognitive issues, sensory impairment, and financial issues. 8 COVID-19 pandemic has further complicated healthcare delivery for older adults. 9 Older adults suffering from chronic health conditions are probably the most affected as they seem to be stuck in a quagmire of risk of illness relapse plus the risk of contracting COVID-19 while accessing healthcare. 10 Older adults also represent an essential cohort in clinical research, given their multiple comorbidities. Hence, there is a need for safe and effective treatment options that are also cost-effective.Transcranial direct current stimulation (tDCS) is emerging as a potential treatment option for depression, cognitive impairment, and auditory hallucinations in older adults. The possibility of promoting neuroplasticity through tDCS without any significant adverse

show abstract

“…Importantly, tDCS has been developed for home use, with remote supervision, providing an advantage for access to treatment (Charvet et al, 2020) and ensuring continuity in the treatment (Bikson et al, 2020). In addition to the portability for remote administration, tES techniques are considered safe and well-tolerated (Bikson et al, 2016;Chhabra et al, 2020). However, even as tDCS is considered to be safe, it remains investigational for many of the potential applications in COVID-19.…”

Section: Role In Managing Acute and Chronic Psychological Conditions mentioning

confidence: 99%

Update on the Use of Transcranial Electrical Brain Stimulation to Manage Acute and Chronic COVID-19 Symptoms

Pilloni

Bikson

Badran

et al. 2020

Front. Hum. Neurosci.

View full text Add to dashboard Cite

The coronavirus disease 19 (COVID-19) pandemic has resulted in the urgent need to develop and deploy treatment approaches that can minimize mortality and morbidity. As infection, resulting illness, and the often prolonged recovery period continue to be characterized, therapeutic roles for transcranial electrical stimulation (tES) have emerged as promising non-pharmacological interventions. tES techniques have established therapeutic potential for managing a range of conditions relevant to COVID-19 illness and recovery, and may further be relevant for the general management of increased mental health problems during this time. Furthermore, these tES techniques can be inexpensive, portable, and allow for trained self-administration. Here, we summarize the rationale for using tES techniques, specifically transcranial Direct Current Stimulation (tDCS), across the COVID-19 clinical course, and index ongoing efforts to evaluate the inclusion of tES optimal clinical care.

show abstract

Tolerance of transcranial direct current stimulation in psychiatric disorders: An analysis of 2000+ sessions

Cited by 28 publications

References 48 publications

Neuromodulation to Treat Substance Use Disorders in People With Schizophrenia and Other Psychoses: A Systematic Review

Neuromodulation to Treat Substance Use Disorders in People With Schizophrenia and Other Psychoses: A Systematic Review

Domiciliary tDCS in Geriatric Psychiatric Disorders: Opportunities and Challenges

Update on the Use of Transcranial Electrical Brain Stimulation to Manage Acute and Chronic COVID-19 Symptoms

Contact Info

Product

Resources

About